HR Execs on the Move


 
MANCEF is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Kyowa Kirin

Kyowa Kirin Co., Ltd.

Transcend Orthotics & Prosthetics

Transcend orthotists and prosthetists are fully certified and experienced in serving the needs of our patients.

CardioRisk

CardioRisk is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.